Biotage (BIOT) Q2 2024 earnings summary

Executive summary

• Returned to organic growth in Q2 2024 with 9.3% organic growth and 23.4% net sales increase; strong performance in Americas and EMEA, while China faced headwinds and operational adjustments were made.

• Recurring revenue increased to 73% in Q2, reflecting a shift toward consumables and services.

• Gross margin expanded by 2.2 percentage points to 64.2% in Q2, supported by new product launches and market momentum.

• Product launches in Drug Discovery & Development (PeptiPEC-96 and Selekt ELSD) expected to contribute significantly.

• CEO transition in January and new financial targets set for double-digit organic growth and upper 20% adjusted EBITDA margin over three years.

Financial highlights

• Q2 2024 revenue/net sales reached 504 MSEK, up 23–23.4% year-over-year; H1 2024 revenue/net sales was 984 MSEK, up 27.9–28%.

• Q2 adjusted EBITDA was 131 MSEK (25.9% margin); H1 adjusted EBITDA was 256 MSEK (26.1% margin).

• Q2 operating profit (EBIT) was 77 MSEK (15.2% margin); Q2 net income was 48 MSEK; EPS was SEK 0.60.

• Q2 adjusted cash flow from operations was 74 MSEK (+47%); H1 adjusted cash flow was 245 MSEK (+108%).

• Q2 gross profit margin was 64.2% (up 2.2 pts); H1 gross margin was 63.7% (up 2.2 pts).

Outlook and guidance

• Market momentum is returning, with continued product innovation and focus on increasing recurring revenue and production capacity.

• Financial targets reaffirmed: average annual double-digit organic revenue growth and upper 20% adjusted EBITDA margin over three years.

• Actions taken in China to align operations with current market conditions.